DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Kallmann syndrome — screening already-approved drugs against its 23-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleKallmann syndrome maps to a 23-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for kallmann syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 1 (FGFR1) — FGFR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methylpiperazin-1-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5A46 · 2.63 Å · ligand 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (38O). Experimental structure, not a prediction.
What the evidence adds up to
In a 2015 MRI study of 14 patients with Kallmann syndrome, 10 had low GnRH and gonadal hormone levels, 11 had hyposmia, and 3 had anosmia. On imaging, olfactory bulbs and bundles were absent bilaterally in 8 patients, absent on the left and hypoplastic on the right in 2, and bilaterally hypoplastic in 4. Olfactory sulci were absent in 5 and hypoplastic in 9. The anterior pituitary was hypoplastic in 6 patients. The authors concluded that MRI has distinctive features that may aid diagnosis in ambiguous clinical cases.
A 1998 retrospective study of 16 patients (11 male, 5 female) treated between 1984 and 1996 reported presenting symptoms including micropenis, small testes, anosmia, and delayed puberty. Fifty-six percent (9/16) had a family history of anosmia or infertility. Associated features included unilateral renal aplasia, coloboma of the iris, deafness, midline anomalies, oculomotor apraxia, and Moebius anomalad. Most patients had low basal gonadotrophins, testosterone or oestrogen, and a poor response to LHRH stimulation, though two showed a pubertal response and may have a variant form. Treatment with exogenous testosterone or oestrogen induced appropriate pubertal progress in each patient.
A 2023 review notes that Kallmann syndrome is characterised by hypogonadotropic hypogonadism and hyposmia or anosmia, with an incidence in males of 1 in 8000 to 1 in 10,000 and less common in females. Over 24 genes are implicated, and inheritance can be autosomal recessive, autosomal dominant, or X-linked. The review states that standard treatment involves hormone replacement therapy with testosterone and GnRH analogues to stimulate puberty and promote secondary sexual characteristics. No drug repurposing data, no novel therapeutic candidates, and no interventional trial results are presented in any of these three papers.
What is still missing is any controlled trial testing a repurposed drug for Kallmann syndrome, any evidence that a non-hormonal agent can restore GnRH neuron migration or olfactory function, and any systematic effort to stratify patients by genetic mutation or MRI phenotype for targeted therapy. The existing literature remains descriptive and focused on hormone replacement, with no data on disease modification.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Computer Assisted Tomography · 2015 · 18 citations
Magnetic Resonance Imaging Findings in Kallmann Syndrome
AbstractPURPOSE: We sought to characterize the magnetic resonance imaging (MRI) findings in patients with Kallmann syndrome (KS). MATERIALS AND METHODS: Fourteen patients with KS and a comparison group of 20 matched people with normal MRI were analyzed with optimized voxel-based morphometry. Coronal T1- and T2-weighted images from the anterior margin of the frontal sinus to the hypothalamus were obtained. The olfactory sulci, bulbs, and bundles were assessed as normal, hypoplastic, or absent. The pituitary gland was also evaluated. RESULTS: Four of the 14 patients came from 1 family. Ten patients had low levels of GnRH and gonadal hormone, 11 had hyposmia, and 3 had anosmia. On MRI, the olfactory bulbs (OBs) and bundles were absent bilaterally in 8 patients. Two patients exhibited absence of the OBs and bundles on the left and hypoplasia on the right. Four patients displayed bilateral hypoplastic OBs and bundles. The olfactory sulci were absent in 5 and hypoplastic in 9 of these patients. The anterior pituitary was hypoplastic in 6 patients. CONCLUSIONS: Kallmann syndrome has distinctive features on MRI. Magnetic resonance imaging may aid in the diagnosis of KS in patients with ambiguous clinical findings.
Journal of Pediatric Endocrinology and Metabolism · 1998 · 14 citations
Clinical Evaluation in Isolated Hypogonadotrophic Hypogonadism (Kallmann Syndrome)
AbstractOBJECTIVE: To describe the clinical features, laboratory investigation and treatment of Kallmann syndrome. DESIGN: A retrospective study of patients treated in the Endocrine Clinic of the Royal Children's Hospital and St Vincent's Hospital, Melbourne, between 1984 and 1996. RESULTS: Eleven males and 5 females with Kallmann syndrome are described. Their ages at presentation ranged from one week to 21 years. Presenting symptoms were micropenis, small testes, anosmia and delayed puberty. Fifty-six percent (9/16) had a family history of either anosmia or infertility. The features of Kallmann syndrome are variable. We have described unilateral renal aplasia, coloboma of iris, deafness, midline anomalies, oculomotor apraxia and Moebius anomalad as features that were associated with Kallmann syndrome in our group of subjects. One patient diagnosed as having X-linked Kallmann syndrome has previously been shown to have a specific mutation in an intronic sequence adjacent to exon 6. Most patients showed low serum levels of basal gonadotrophins, testosterone or oestrogen, and had a poor response to LHRH stimulation, but two patients showed a pubertal response to LHRH stimulation, and may have a variant form of Kallmann syndrome. Treatment given to these patients included exogenous testosterone or oestrogen for induction of puberty, with appropriate pubertal progress occurring in each patient. CONCLUSION: The manifestations of Kallmann syndrome vary, depending upon the degree of LHRH deficiency. Therapy should combine exogenous sex hormone replacement and psychological support, with long-term follow-up to ensure maintenance of normal sexual function, normal bone mass and psychosocial outcome, with fertility induction when indicated.
Research Journal of Pharmacology and Pharmacodynamics · 2023 · 0 citations
Facing the Challenge: Hormonal hurdles, Olfaction Obstacles in Kallmann Syndrome
AbstractKallmann syndrome (KS) is an uncommon disorder that was first defined in 1856 and designed by Kallmann in 1944. It is also referred to as olfactogenital dysplasia and is characterized by hypogonadism and the agenesis of the olfactory bulb. The prevalence of KS is not well understood, with the incidence in males ranging from 1 in 8000 to 1 in 10,000 and being less common in females. Kallmann syndrome exhibits genetic heterogeneity, with the inheritance of the trait occurring in an autosomal recessive, autosomal dominant, or X-linked manner. Over 24 genes have been determined to be responsible for Kallmann syndrome, which is thought to be caused by mutations that inhibit the formation of cell markers necessary for the migration of olfactory and GnRH (gonadotropin-releasing hormone) neurons to the forebrain during foetal development. Kallmann syndrome is characterised by hypogonadotropic hypogonadism and hyposmia or anosmia. Other less common symptoms include osteoporosis, cleft lip and palate, cryptorchidism, unilateral renal agenesis, and cardiovascular problems. Magnetic resonance imaging (MRI) can help detect anomalies in the olfactory system and other forebrain regions, as well as pituitary disorders. The treatment for Kallmann syndrome typically involves hormone replacement therapy (HRT) with both testosterone and gonadotropin-releasing hormone (GnRH) analogues to stimulate puberty and promote secondary sexual characteristics.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
